Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer

Inclusion Criteria:

1. The Patients (or legally authorized representative) Patients (or legallyauthorized representative) must have the ability to understand the requirementsof the study, have provided written informed consent as evidenced by signatureon an informed consent form (ICF) approved by an Institutional ReviewBoard/Independent Ethics Committee (IRB/IEC) ,must have the ability tounderstand the requirements of the study);

2. The patient must be 18 to 70 years of age at the time of consent;

3. Must have a confirmed diagnosis of malignancy of their receptive histologies orcytology: unresectable recurrent or metastatic cervical carcinomas andpreviously received≥ 1 prior systemic therapy;

4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

5. Expected survival time of ≥ 12 weeks;

6. Adequate normal organ and marrow function;

7. Before tumor resection, the confirmatory imaging of disease progress since lasttreatment should be documented.

• 8.Patients must have measurable disease measured by Response Evaluation Criteria inSolid Tumors (RECIST) 1.1 criteria (in addition to the resected lesion).

Exclusion Criteria:

• 1.Patients with uncontrollable tumor-related pain as judged by the investigator;participants requiring painkiller must already have had a stable pain managementoptions at the time of study entry; symptomatic lesions suitable for palliativeradiotherapy should be completed prior to study entry;

• 2.Patients who have psychiatric disorders, alcohol, drug or substance abuse;

• 3.Women who are pregnant or breastfeeding, or planning to become pregnant within 1year after cell infusion;

• 4.Participate in other clinical trials within 4 weeks prior to screening, orplanning to participate in this study and other clinical trials at the same time;

• 5.Any other conditions that would make the patient unsuitable candidate for thestudy at the discretion of the investigator.